Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Expected to Announce Earnings of -$0.23 Per Share

Wall Street brokerages predict that Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will post earnings per share of ($0.23) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Alpine Immune Sciences’ earnings, with the lowest EPS estimate coming in at ($0.41) and the highest estimate coming in at ($0.14). Alpine Immune Sciences reported earnings of ($0.62) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 62.9%. The business is expected to announce its next quarterly earnings report on Wednesday, November 11th.

According to Zacks, analysts expect that Alpine Immune Sciences will report full year earnings of ($1.29) per share for the current fiscal year, with EPS estimates ranging from ($1.70) to ($1.08). For the next financial year, analysts expect that the business will report earnings of ($0.62) per share, with EPS estimates ranging from ($1.37) to $0.14. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPN) last released its quarterly earnings data on Tuesday, August 11th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.30). Alpine Immune Sciences had a negative net margin of 1,120.46% and a negative return on equity of 125.54%. The company had revenue of $0.69 million during the quarter, compared to the consensus estimate of $2.13 million.

Several analysts recently issued reports on the stock. ValuEngine downgraded shares of Alpine Immune Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. Piper Sandler reduced their price target on shares of Alpine Immune Sciences from $21.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Oppenheimer reissued a “buy” rating and issued a $19.00 price target on shares of Alpine Immune Sciences in a research report on Wednesday, August 12th. Zacks Investment Research raised shares of Alpine Immune Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 13th. Finally, Cowen started coverage on shares of Alpine Immune Sciences in a report on Wednesday, August 26th. They set an “outperform” rating on the stock. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $16.00.

NASDAQ ALPN opened at $8.72 on Tuesday. The company has a fifty day simple moving average of $8.18 and a 200 day simple moving average of $6.88. Alpine Immune Sciences has a 12-month low of $2.05 and a 12-month high of $15.00. The company has a current ratio of 3.24, a quick ratio of 3.24 and a debt-to-equity ratio of 0.61. The company has a market cap of $207.41 million, a P/E ratio of -4.90 and a beta of 1.18.

Institutional investors and hedge funds have recently bought and sold shares of the business. Berman Capital Advisors LLC bought a new position in Alpine Immune Sciences in the second quarter worth $529,000. Ikarian Capital LLC bought a new position in Alpine Immune Sciences in the second quarter worth $46,000. Finally, Leonard Rickey Investment Advisors P.L.L.C. raised its holdings in Alpine Immune Sciences by 70.1% in the third quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 17,013 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 7,013 shares in the last quarter. 29.95% of the stock is currently owned by hedge funds and other institutional investors.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.

Read More: What is a recession?

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.